9 January 2002

Contents

Conference reports

• 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 16-19 December 2001

• Low dose pegylated interferon is ineffective in treating HIV/HCV co-infected patients

• Phenotypic resistance to ddI is less frequent than resistance to ZDV, 3TC and abacavir

• Impact of Kaletra on amprenavir plasma concentrations in HIV treatment-experienced patients

• Immune reconstitution more difficult with low baseline CD4+ T cell counts

• HIV-1 may revert to less pathogenic strain a few days after starting HAART

• Change from CCR5 to CXCR4 phenotype may affect immunologic responses

• ddI EC (Videx) study confirms and clarifies dosing on an empty stomach

• Swatch study: should we be cycling drugs?

• New HIV drugs, resistance, pharmacogenomics

• Antiretroviral therapy

• Immunopathogenesis of HIV infection

Basic science and immunology

• New findings explain T-cell loss in HIV infection

Other news

• Voluntary suspension of Kava-kava sales following safety concerns

• The Chapman Clinic: musculoskeletal treatment for patients with HIV

On the web

• Additional reports from ICAAC 2001

• Double scourge: tuberculosis and HIV coinfection

• The road to eradication: is HAART hard enough?